

Anti-Tumor Effect in MLLr AML Xenograft Model MV-4-11




FIG. 1

Anti-Tumor Effect in MLLr AML Xenograft Model MOLM-13




FIG. 2A

Anti-Tumor Effect in MILLr AML Xenograft Model MOLM-13




FIG. 2B

A. Effect of Treatment on Survival in MLLR AML Patient Derived
Disseminated Xenograft Mouse Model CBAM-68552




FIG. 3-A

B. Effect of Treatment on Survival in MLLR AML Patient Derived
Disseminated Xenograft Mouse Model CBAM-44728




FIG. 3-B

C. Effect of Treatment on Survival in MLLR AML Patient Derived
Disseminated Xenograft Mouse Model DFAL-49600




FIG. 3-C

Anti-Tumor Effect in NPM1 mutant AML Patient Derived Disseminated Xenograft Model DFAM-16835




FIG. 4

Combination Signal Heatmap (% Cell Viability) in MOLM-13 Cell Line (Compound 56-2/Venetoclax)




FIG. 5

Anti-Tumor Effect in NPM1 mutant AML Patient Derived Disseminated Xenograft Model DFAM-16835
(Compound 56-2 in Combination with Venetoclax)




FIG. 6




FIG. 7-A

B. Effect of Treatment on Menin Protein Levels in MV-4-11 Cell Line (Compound 56-2)




FIG. 7-B

C. Effect of Treatment on Total Menin Protein Levels in MV-4-11 Cell Line (DMSO/Compound 56-2)




FIG. 7-C